| Autor: |
Kim, Sara S, Chung, Jessie R, Belongia, Edward A, McLean, Huong Q, King, Jennifer P, Nowalk, Mary Patricia, Zimmerman, Richard K, Balasubramani, Goundappa K, Martin, Emily T, Monto, Arnold S, Lamerato, Lois E, Gaglani, Manjusha, Smith, Michael E, Dunnigan, Kayan M, Jackson, Michael L, Jackson, Lisa A, Tenforde, Mark W, Verani, Jennifer R, Kobayashi, Miwako, Schrag, Stephanie J |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 11/15/2021, Vol. 224 Issue 10, p1694-1698, 5p |
| Abstrakt: |
Evaluations of vaccine effectiveness (VE) are important to monitor as coronavirus disease 2019 (COVID-19) vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged ≥16 years, the VE of messenger RNA vaccines against COVID-19 was 91% (95% confidence interval, 83%-95%) for full vaccination and 75% (55%-87%) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
